Ikarian Capital, LLC Affimed N.V. Transaction History

Ikarian Capital, LLC

  • $573 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$5.54 - $7.51 $515,774 - $699,181
-93,100 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$7.78 - $11.4 $724,318 - $1.06 Million
93,100 New
93,100 $792,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email